Clinical Trials Logo

Multicentric Castleman Disease clinical trials

View clinical trials related to Multicentric Castleman Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT05663502 Recruiting - Lymphoma Clinical Trials

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

Start date: May 10, 2023
Phase:
Study type: Observational

This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)-related cancers. Collecting blood and tissue samples and studying biomarkers in the laboratory may help doctors to learn how are biologic or genetic factors related to HIV and cancers that occur commonly in people living with HIV.

NCT ID: NCT04585893 Recruiting - Clinical trials for Multicentric Castleman Disease

Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi

Start date: June 22, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of first-line, risk-stratified Rituximab-based Multicentric Castleman Disease (MCD) treatment in Malawi in a single-arm, phase II clinical trial. This study also aims to compare the cost-effectiveness of first-line Rituximab treatment for MCD in Malawi to chemotherapy.

NCT ID: NCT03043105 Active, not recruiting - Clinical trials for Multicentric Castleman Disease

TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial

Start date: January 1, 2017
Phase: Phase 2
Study type: Interventional

To explore the effectiveness and safety of thalidomide, cyclophosphamide and prednisone (TCP regimen) in newly diagnosed Multicentric Castleman's disease (MCD) patients.

NCT ID: NCT01441063 Completed - Castleman Disease Clinical Trials

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

Start date: September 13, 2011
Phase: Phase 2
Study type: Interventional

Background: - Kaposi's sarcoma-associated herpes virus (KSHV)-associated multicentric Castleman disease (KSHV-MCD) is caused by a herpes virus known as KSHV. This disease can also cause several other cancers, including Kaposi sarcoma. People with KSHV-MCD often have symptoms like fever, weight and muscle loss, and fluid in the legs or abdomen. Tocilizumab may be able to block the chemicals in the body that cause KSHV-MCD symptoms. Researchers want to test this drug and other anti-virus drugs to find the best combination of drugs to treat KSHV-MCD. Objectives: - To test the effectiveness of tocilizumab with and without other anti-virus drugs for KSHV-MCD. Eligibility: - People at least 18 years of age who have KSHV-MCD and have certain symptoms and blood abnormalities caused by their KSHV-MCD. Design: - Participants will be screened with a medical history and physical exam. They will also have blood tests, and a skin biopsy. - Participants will have tocilizumab injections every 2 weeks for up to 12 weeks. They will provide daily blood samples for the first 3 days of treatment. - After the sixth dose, participants will be monitored for 4 weeks to check for possible side effects. - Those whose KSHV-MCD does not improve or worsens during the study may have tocilizumab combined with two other anti-virus drugs, zidovudine and valganciclovir. These drugs are pills that will be taken four times a day for 5 days out of every 2 weeks. - Blood, urine, and saliva samples will be collected throughout the study.